Leczenie eksperymentalne COVID-19

Z Wikipedii, wolnej encyklopedii
Przejdź do nawigacji Przejdź do wyszukiwania

Leczenie eksperymentalne COVID-19 – strategie terapeutyczne mające na celu znalezienie leków skutecznych w zwalczaniu choroby COVID-19.

Do połowy marca 2020 nie zostały opracowane lekarstwa ani szczepionki leczące lub zapobiegające zakażeniu SARS-CoV-2. W związku z pandemią wirusa SARS-CoV-2 w 2020 r. w wielu ośrodkach na świecie rozpoczęto intensywne poszukiwania leków mających zastosowanie w leczeniu COVID-19[1]. Do analizowanych terapii zaliczają się procedury z wykorzystaniem leków przeciwwirusowych, przeciwciał monoklonalnych, peptydów, oligonukleotydów, interferonów, a także szczepionki. W celu jak najszybszego wprowadzenia leków na COVID-19 badane są możliwości wykorzystania istniejących leków mających dotychczas inne zastosowania. Można do nich zaliczyć m.in. leki przeciw wirusom HIV, HBV, HCV, grypy oraz inne, oparte na doświadczeniu w leczeniu infekcji wywołanych przez koronawirusy, takich jak SARS i MERS[1][2][3]. Większość badań klinicznych dotyczących leczenia COVID-19 zostało uruchomionych w Chinach[4]. Największą grupę potencjalnych leków stanowią środki wykorzystywane w tradycyjnej medycynie chińskiej (32%), czasem w kombinacji z tradycyjną medycyną zachodnią (15%). Ponadto badane są znane leki przeciwwirusowe (23%), bioterapeutyki (interferony, komórki macierzyste, immunoterapeutyki i in.) (15%) i leki przeciwmalaryczne (10%), a także, a mniejszym stopniu glikokortykoidy (3%), i osocze (2%)[4].

Lista leków eksperymentalnych stosowanych w leczeniu COVID-19
Lek Lokalizacja badania
Remdesiwir Hubei, Chiny[5]

Pekin, Chiny[6]

międzynarodowe[7]

inne[8][9]

Hiszpania[10][11]

Lopinawir + rytonawir Wuhan, Chiny[12][5][13]

Guangdong, Chiny[6][14]

Hongkong[8]

Uniwersytet Zhejiang, Chiny[9]

Jiangxi, Chiny[15][16]

Chongqing, Chiny[17][18]

Hubei, Chiny[19][20]

różne miasta[21][22]

Syczuan, Chiny[23]

Zhejiang, Chiny[24]

Zhuhai, Chiny[25]

Lopinawir Zhejiang, Chiny[26]
ASC09 + rytonawir Uniwersytet Zhejiang, Chiny[9]; Chongqing, Chiny[18]
Danoprewir + rytonawir Jiangxi, Chiny[15]
Fawipirawir Zhejiang, Chiny[24]

Guangdong, Chiny[27][28]

Pekin, Chiny[29]

Wuhan, Chiny[30]

Fawipirawir + bromoheksyna Zhejiang, Chiny[31]
Rybawiryna Hong kong[8]Chongqing, Chiny[17]
Umifenowir Chongqing, Chiny[18]

różne miasta, Chiny[21]

Tongji, Chiny[32]

Szanghaj, Chiny[33]

Zhejiang, Chiny[26]

Szanghaj, Chiny[34][35]

Hubei, Chiny[36][37]

Ruijin, Chiny[38]

Komórki macierzyste Hubei, Chiny[39][40][41][42][43][44][45][46]

Pekin, Chiny[47]

Zhejiang, Chiny[48]

Chiny[49][50][51]

Guangdong, Chiny[52][53][54][55]

Pekin, Hubei, Szanghaj, Chiny[56]

Pekin, Chiny[57]

Jiangxi, Chiny[58]

nieznana[59]

Darunawir + kobicystat Szanghaj, Chiny[60]

Hubei, Chiny[61]

Azwudyna Henan, Chiny[62][63][64]
Triazawiryna Heilongjiang, Chiny[65]
Emtrycytabina Syczuan, Chiny[23]
Marboksyl baloksawiru Zhejiang, Chiny[24]

Guangdong, Chiny[27]

Alafenamid tenofowiru Syczuan, Chiny[23]
Nowaferon Jiangxi, Chiny[15]Zhejiang, Chiny[26]
Peginterferon alfa-2a Jiangxi, Chiny[15]
Interferon beta-1b Hong kong[8]
Interferon alfa-1b Chongqing, Chiny[17]Tongji, Chiny[66]

Hubei, Chiny[67]

Interferon Syczuan, Chiny[68]

Hunan, Chiny[69]

Szanghaj, Chiny[70]

Tradycyjne leki chińskie Jiangxi, Chiny[15]
Chlorochina różne miasta, Chiny[21]

Szanghaj, Chiny[71] Guangdong, Chiny[72][14][73]

Hubei, Chiny[74]

Zhunghai, Chiny[25]

Hubei, Chiny[75][76][77]

Chongqing, Chiny[78][79]różne miasta, Chiny[80][81][82]

Jilin, Chiny[83]

Heilongjiang, China[84]

Hydroksychlorochina różne miasta, Chiny[80][81][82]

Hubei, Chiny[77][37]

Francja[85]

Karrimycyna różne miasta, Chiny[21][86]
Oseltamiwir Tongji, Chiny[87]
Przeciwciała Chiny[88]
Immunoglobuliny Tongji, Chiny[89]

Hubei, Chiny[90]

Metyloprednizolon Pekin, Chiny[91]

Tongji, Chiny[92]

Hubei, Chiny[93][94]

Chongqing, Chiny[95]

Dezaktywowane osocze przeciw wirusowi SARS-CoV-2 Hubei, Chiny[96][97][98][99]
Osocze pobrane od rekonwalescentów Zhejiang, Chiny[100]

Jiangsu, Chiny[101]

Meplazumab Shaanxi, Chiny[102]
Bewacyzumab Shandong, Chiny[103]
Ekulizumab USA[104]
Tocilizumab Anhui, Chiny[105]

Shaanxi, Chiny[106]

Adalimumab Szanghaj, Chiny[107]
vMIP Hubei, China[108]
Komórki NK Henan, Chiny[109]
Cytokiny Shaanxi, Chiny[110]
Makrofagi Chiny[111]
Tymozyna Chiny[88][112]
Fingolimod Fuzhou, Chiny[113]
Pirfenidon Hubei, Chiny[114][115]
Kwas poliinozyno-policytydylowy (pIC) Zheijang, Chiny[116]
Leflunomid Hubei, Chiny[117]
Dihydroartemizynina/piperachin Jiangxi, Chiny[118]
Tlenek azotu Chiny[119][120]
Ciągłe pozaustrojowe natlenianie krwi Chiny[121]
Talidomid Chiny[122][123]
Dipirydamol Chiny[124]
Acetylocysteina Hubei, Chiny[125]
Zasadowy cytrynian bizmutawy Wuhan, Chiny[126]

Zobacz też[edytuj | edytuj kod]

Przypisy[edytuj | edytuj kod]

  1. a b Guangdi Li, Erik De Clercq, Therapeutic options for the 2019 novel coronavirus (2019-nCoV), „Nature Reviews. Drug Discovery”, 19 (3), 2020, s. 149–150, DOI10.1038/d41573-020-00016-0, PMID32127666 (ang.).
  2. Charlotte Harrison, Coronavirus puts drug repurposing on the fast track, „Nature Biotechnology”, 2020, DOI10.1038/d41587-020-00003-1 (ang.).
  3. Repurposed drugs may help scientists fight the new coronavirus, Science News, 10 marca 2020 [dostęp 2020-03-15] (ang.).
  4. a b Qi Zhang i inni, Clinical trial analysis of 2019-nCoV therapy registered in China, „Journal of Medical Virology”, 2020, DOI10.1002/jmv.25733, PMID32108352 (ang.).
  5. a b Bin Cao, Yeming Wang, Mild/Moderate 2019-nCoV Remdesivir RCT, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04252664 [dostęp 2020-03-14] (ang.).
  6. a b Bin Cao, Severe 2019-nCoV Remdesivir RCT, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04257656 [dostęp 2020-03-14] (ang.).
  7. John Herbert Beigel, Adaptive COVID-19 Treatment Trial, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04280705 [dostęp 2020-03-14] (ang.).
  8. a b c d A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment, Gilead Sciences, fdaaa.trialstracker.net, NCT04292730 [dostęp 2020-03-14].
  9. a b c A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe COVID-19, Gilead Sciences, fdaaa.trialstracker.net, NCT04292899 [dostęp 2020-03-14].
  10. A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment. EudraCT Number: 2020-000842-32, www.clinicaltrialsregister.eu, dostęp 03.15.2020
  11. A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19 EudraCT Number: 2020-000841-15, www.clinicaltrialsregister.eu, dostęp 03.15.2020
  12. Qing Ning, Meifang Han, A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04255017 [dostęp 2020-03-14] (ang.).
  13. Zhang Dingyu, A randomized, controlled open-label trial to evaluate the efficacy and safety of lopinavir-ritonavir in hospitalized patients with novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029308 [dostęp 2020-03-14].
  14. a b A prospective, open-label, multiple-center study for the efficacy of chloroquine phosphate in patients with novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029609 [dostęp 2020-03-15].
  15. a b c d e Hongyi Chen, Zhicheng Zhang, Evaluation of Ganovo (Danoprevir ) Combined With Ritonavir in the Treatment of Novel Coronavirus Infection, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04291729 [dostęp 2020-03-14] (ang.).
  16. Xie Liangdong, Study of Pinavir / Ritonavir Tablets (Trade Name: Kelizhi) Combined with Xiyanping Injection for Novel Coronavirus Pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030218 [dostęp 2020-03-14].
  17. a b c 2019-nCoV Community Effort - Targeting 2019-nCoV Portal, ghddi-ailab.github.io, ChiCTR2000029387 [dostęp 2020-03-14].
  18. a b c Peng Hu, Retracted due to lack of patient A multicenter, randomized, open label, controlled trial for the efficacy and safety of ASC09/ Ritonavir compound tablets and Lopinavir/ Ritonavir (Kaletra) and Arbidol tablets in the treatm, www.chictr.org.cn, ChiCTR2000029759 [dostęp 2020-03-14].
  19. Jianping Zhao, A randomized, open-label study to evaluate the efficacy and safety of Lopinavir-Ritonavir in patients with mild novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029539 [dostęp 2020-03-14].
  20. Zhijian Luo, Wei Xiao, Clinical study for Lopinavir and Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19), apps.who.int, ChiCTR2000030187 [dostęp 2020-03-14].
  21. a b c d Huiguo Ding, Ying Han, The Clinical Study of Carrimycin on Treatment Patients With COVID-19, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04286503 [dostęp 2020-03-14] (ang.).
  22. 新型コロナに対する臨床試験を全調査、ゾフルーザやアビガンの成分活用:日経バイオテクONLINE, bio.nikkeibp.co.jp, ChiCTR2000029468, ChiCTR2000029387, ChiCTR2000029386 [dostęp 2020-03-14].
  23. a b c Ting Li, Hua Jiang, A real-world study for lopinavir/ritonavir (LPV/r) and emtritabine (FTC) / Tenofovir alafenamide Fumarate tablets (TAF) regimen in the treatment of novel coronavirus pneumonia (COVID-19), apps.who.int, ChiCTR2000029468 [dostęp 2020-03-14].
  24. a b c Jianzhong Shentu, Qiu Yunqing, Randomized, open-label, controlled trial for evaluating of the efficacy and safety of Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) patients, www.chictr.org.cn, ChiCTR2000029548 [dostęp 2020-03-14].
  25. a b Efficacy of Chloroquine and Lopinavir/ Ritonavir in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label, multicenter randomized controlled clinical study, www.chictr.org.cn, ChiCTR2000029741 [dostęp 2020-03-15].
  26. a b c A multicenter, randomized, open, controlled clinical study to evaluate the efficacy and safety of recombinant cytokine gene-derived protein injection in combination with standard therapy in patients with novel coronavirus infection, www.chictr.org.cn, ChiCTR2000029573 [dostęp 2020-03-14].
  27. a b A randomized controlled trial for the efficacy and safety of Baloxavir Marboxil, Favipiravir tablets in novel coronavirus pneumonia (COVID-19) patients who are still positive on virus detection under the current antiviral therapy, www.chictr.org.cn, ChiCTR2000029544 [dostęp 2020-03-14].
  28. Randomized controlled trial for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19) with poorly responsive ritonavir/ritonavir, www.chictr.org.cn, ChiCTR2000030113 [dostęp 2020-03-14].
  29. A randomized, open-label, controlled trial for the efficacy and safety of Farpiravir Tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029996 [dostęp 2020-03-14].
  30. A randomized, open-controlled trial for farpiravir tablets in the treatment of novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030254 [dostęp 2020-03-14].
  31. Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19), [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04273763 [dostęp 2020-03-14] (ang.).
  32. A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04254874 [dostęp 2020-03-14] (ang.).
  33. Clinical study of arbidol hydrochloride tablets in the treatment of novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029621 [dostęp 2020-03-14].
  34. Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04260594 [dostęp 2020-03-14] (ang.).
  35. Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04260594 [dostęp 2020-03-15] (ang.).
  36. Study for Arbidol Hydrochloride in the Prophylaxis of Novel Coronavirus Infection in High-risk Population with History of Exposed to COVID-19 pneumonia, www.chictr.org.cn, ChiCTR2000029592 [dostęp 2020-03-14].
  37. a b A prospective, randomized, open-label, parallel controlled clinical study to evaluate the preventive effect of hydroxychloroquine on medical personnel after exposure to novel coronavirus (COVID-19), www.chictr.org.cn, ChiCTR2000029803 [dostęp 2020-03-15].
  38. Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04260594 [dostęp 2020-03-15] (ang.).
  39. Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19), [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04288102 [dostęp 2020-03-14] (ang.).
  40. Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04293692 (ang.).
  41. Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04273646 [dostęp 2020-03-14] (ang.).
  42. Safety and efficacy of umbilical cord blood mononuclear cells conditioned medium in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled tria, www.chictr.org.cn, ChiCTR2000029569 [dostęp 2020-03-14].
  43. Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically novel coronavirus pneumonia(COVID-19): a randomized controlled clinical trial, www.chictr.org.cn, ChiCTR2000029572 [dostęp 2020-03-14].
  44. Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04269525 [dostęp 2020-03-14] (ang.).
  45. Clinical study of mesenchymal stem cells in treating severe novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030224 [dostęp 2020-03-14].
  46. Umbilical cord mesenchymal stem cells (hucMSCs) in the treatment of high risk novel coronavirus pneumonia (COVID-19) patients, www.chictr.org.cn, ChiCTR2000030300 [dostęp 2020-03-14].
  47. Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04252118 [dostęp 2020-03-14] (ang.).
  48. Clinical Study for Human Menstrual Blood-Derived Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029606 [dostęp 2020-03-14].
  49. A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04276987 [dostęp 2020-03-14] (ang.).
  50. Clinical Trial for Human Mesenchymal Stem Cells in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030138 [dostęp 2020-03-14].
  51. Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04302519 [dostęp 2020-03-14] (ang.).
  52. Clinical Study for Umbilical Cord Blood Mononuclear Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029812 [dostęp 2020-03-14].
  53. Clinical Study for Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029816 [dostęp 2020-03-14].
  54. Clinical Study of Cord Blood NK Cells Combined with Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029817 [dostęp 2020-03-14].
  55. Clinical Study for Umbilical Cord Blood Plasma in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029818 [dostęp 2020-03-14].
  56. Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029990 [dostęp 2020-03-14].
  57. Umbilical cord Wharton's Jelly derived mesenchymal stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030088 [dostęp 2020-03-14].
  58. Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030116 [dostęp 2020-03-14].
  59. Clinical Application of Stem Cell Educator Therapy for the Treatment of Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), fdaaa.trialstracker.net, NCT04299152 [dostęp 2020-03-14].
  60. Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04252274 [dostęp 2020-03-14] (ang.).
  61. A randomised, open, controlled trial for darunavir/cobicistat or Lopinavir/ritonavir combined with thymosin a1 in the treatment of novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029541 [dostęp 2020-03-14].
  62. A randomized, open-label, controlled clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029853 [dostęp 2020-03-14].
  63. A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030424 [dostęp 2020-03-14].
  64. A single-arm, single-center clinical trial for Azivudine tablets in the treatment of adult novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030041 [dostęp 2020-03-14].
  65. The efficacy and safety of Triazavirin for 2019 novel coronary pneumonia (COVID-19): a multicenter, randomized, double blinded, placebo-controlled trial, www.chictr.org.cn, ChiCTR2000030001 [dostęp 2020-03-14].
  66. Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04293887 [dostęp 2020-03-15] (ang.).
  67. A prospective clinical study for recombinant human interferon alpha 1b spray in the prevention of novel coronavirus (COVID-19) infection in highly exposed medical staffs., www.chictr.org.cn, ChiCTR2000030013 [dostęp 2020-03-15].
  68. Multicenter randomized controlled trial for novel recombinant high-efficiency compound interferon in the treatment of novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029638 [dostęp 2020-03-15].
  69. A randomized, open label, parallel controlled trial for evaluating the efficacy of recombinant cytokine gene-derived protein injection in eliminating novel coronavirus in patients with novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029496 [dostęp 2020-03-15].
  70. Clinical study for combination of anti-viral drugs and type I interferon and inflammation inhibitor TFF2 in the treatment of novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030262 [dostęp 2020-03-15].
  71. Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV ( HC-nCoV ), [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04261517 [dostęp 2020-03-15] (ang.).
  72. Study for the efficacy of chloroquine in patients with novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029542 [dostęp 2020-03-15].
  73. A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030031 [dostęp 2020-03-15].
  74. Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029559 [dostęp 2020-03-15].
  75. Efficacy of therapeutic effects of hydroxycholoroquine in novel coronavirus pneumonia (COVID-19) patients(randomized open-label control clinical trial), www.chictr.org.cn, ChiCTR2000029740 [dostęp 2020-03-15].
  76. Clinical Study of Chloroquine Phosphate in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029988 [dostęp 2020-03-15].
  77. a b A prospective, open label, randomized, control trial for chloroquine or hydroxychloroquine in patients with mild and common novel coronavirus pulmonary (COVIP-19), www.chictr.org.cn, ChiCTR2000030054 [dostęp 2020-03-15].
  78. A randomized, open-label, controlled trial for the efficacy and safety of hydroxychloroquine sulfate tablets in the treatment of patients with severe novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029762 [dostęp 2020-03-15].
  79. Clinical study on the safety and effectiveness of Hydroxychloroquine Sulfate tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029761 [dostęp 2020-03-15].
  80. a b Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Mild and Commen Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-label, Parallel, Controlled Trial, www.chictr.org.cn, ChiCTR2000029899 [dostęp 2020-03-15].
  81. a b Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Severe Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-Label, Parallel, Controlled Trial, www.chictr.org.cn, ChiCTR2000029898 [dostęp 2020-03-15].
  82. a b A prospective, randomized, open label, controlled trial for chloroquine and hydroxychloroquine in patients with severe novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029992 [dostęp 2020-03-15].
  83. Single arm study for exploration of chloroquine phosphate aerosol inhalation in the treatment of novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029975 [dostęp 2020-03-15].
  84. Efficacy and safety of chloroquine phosphate inhalation combined with standard therapy in the treatment of novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030417 [dostęp 2020-03-15].
  85. Treatment of Coronavirus SARS-Cov2 Respiratory Infections with Hydroxychloroquine. Clinical trials for eudract_number:2020-000890-25. www.clinicaltrialsregister.eu, dostęp 15.03.2020
  86. The efficacy and safety of carrimycin treatment in patients with novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial, www.chictr.org.cn [dostęp 2020-03-14].
  87. A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04261270 [dostęp 2020-03-14] (ang.).
  88. a b Immunoregulatory Therapy for 2019-nCoV, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04268537 [dostęp 2020-03-15] (ang.).
  89. The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04261426 [dostęp 2020-03-15] (ang.).
  90. Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04264858 [dostęp 2020-03-15] (ang.).
  91. Glucocorticoid Therapy for Novel Coronavirus Critically Ill Patients With Severe Acute Respiratory Failure, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04244591 [dostęp 2020-03-15] (ang.).
  92. The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04263402 [dostęp 2020-03-15] (ang.).
  93. Efficacy and Safety of Corticosteroids in COVID-19, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04273321 [dostęp 2020-03-15] (ang.).
  94. A randomized, open-label study to evaluate the efficacy and safety of low-dose corticosteroids in hospitalized patients with novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029656 [dostęp 2020-03-15].
  95. Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: protocol of a randomized controlled trial, www.unboundmedicine.com, ChiCTR2000029386 [dostęp 2020-03-15] (ang.).
  96. A randomized, double-blind, parallel-controlled, trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19), www.chictr.org.cn, ChiCTR2000030010 [dostęp 2020-03-15].
  97. A single arm trial to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of novel coronavirus pneumonia patient (COVID-19), www.chictr.org.cn, ChiCTR2000030046 [dostęp 2020-03-15].
  98. Cancelled by investigator A randomized, open-label, controlled and single-center trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient, www.chictr.org.cn, ChiCTR2000030381 [dostęp 2020-03-15].
  99. Cancelled, due to modify the protocol A single-center, open-label and single arm trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment, www.chictr.org.cn, ChiCTR2000030312 [dostęp 2020-03-15].
  100. Study on convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029850 [dostęp 2020-03-15].
  101. Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030039 [dostęp 2020-03-15].
  102. Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04275245 [dostęp 2020-03-15] (ang.).
  103. Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04275414 [dostęp 2020-03-15] (ang.).
  104. Eculizumab (Soliris) in Covid-19 Infected Patients, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04288713 [dostęp 2020-03-15] (ang.).
  105. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029765 [dostęp 2020-03-15].
  106. Cancelled by the investigator Combination of Tocilizumab, IVIG and CRRT in severe patients with novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030442 [dostęp 2020-03-15].
  107. A clinical study for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030089 [dostęp 2020-03-15].
  108. Efficacy and safety of aerosol inhalation of vMIP in the treatment of novel coronavirus pneumonia (COVID-19): a single arm clinical trial, www.chictr.org.cn, ChiCTR2000029636 [dostęp 2020-03-15].
  109. NK Cells Treatment for Novel Coronavirus Pneumonia, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04280224 [dostęp 2020-03-15] (ang.).
  110. Cancelled by the investigator Clinical trial for umbilical cord blood CIK and NK cells in the treatment of mild and general patients infected with novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030329 [dostęp 2020-03-15].
  111. Clinical study for the remedy of M1 macrophages target in the treatment of novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029431 [dostęp 2020-03-15].
  112. Immunomodulatory Therapy for Severe Novel Coronavirus Pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029806 [dostęp 2020-03-15].
  113. Fingolimod in COVID-19, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04280588 [dostęp 2020-03-15] (ang.).
  114. A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04282902 [dostęp 2020-03-15] (ang.).
  115. A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04282902 [dostęp 2020-03-15] (ang.).
  116. A randomized, open-label, blank-controlled, multicenter trial for Polyinosinic-Polycytidylic Acid Injection in the treatment of novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029776 [dostęp 2020-03-15].
  117. A multicenter, randomized, double-blind, controlled clinical trial for leflunomide in the treatment of novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030058 [dostęp 2020-03-15].
  118. Cancelled by the investigator Randomized controlled trial for the efficacy of dihydroartemisinine piperaquine in the treatment of mild/common novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030082 [dostęp 2020-03-15].
  119. Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04290858 [dostęp 2020-03-15] (ang.).
  120. Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04290871 [dostęp 2020-03-15] (ang.).
  121. Clinical Application of ECMO in the Treatment of Patients with Very Serious Respiratory Failure due to novel Coronavirus Pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029804 [dostęp 2020-03-15].
  122. The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04273581 [dostęp 2020-03-15] (ang.).
  123. The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04273529 [dostęp 2020-03-15] (ang.).
  124. Multicenter study for the treatment of Dipyridamole with novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030055 [dostęp 2020-03-15].
  125. Clinical application of inhaled acetylcysteine solution in the treatment of novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030328 [dostęp 2020-03-15].
  126. A randomized, double-blind, placebo-controlled trial for evaluation of the efficacy and safety of bismuth potassium citrate capsules in the treatment of patients with novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030398 [dostęp 2020-03-15].

Star of life.svg Przeczytaj ostrzeżenie dotyczące informacji medycznych i pokrewnych zamieszczonych w Wikipedii.